Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1
Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference
Authors Naegel, Obermann M
Published 22 December 2009 Volume 2010:6(1) Pages 17—28
DOI https://doi.org/10.2147/NDT.S6459
Review by Single anonymous peer review
Peer reviewer comments 3
Steffen Naegel, Mark Obermann
Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany
Abstract: Migraine is a very common disorder characterized by the combination of typical headache with associated autonomic symptoms and/or the presence of aura. Considerable advances have been made in recent years to understand the pathophysiology of migraine, which has led to improved treatment options for the acute migraine attack as well as migraine prophylaxis. Unfortunately, preventive treatment is often insufficient to decrease migraine frequency substantially or is not well tolerated. Topiramate is an antipileptic drug with a complex mode of action which has proven its efficacy and safety in the prophylactic treatment of episodic migraine in a number of randomized controlled clinical trials. Topiramate is also effective in treating patients with chronic migraine. It has little pharmacological interaction with other drugs and is generally well tolerated by patients.
Keywords: migraine, antiepileptic drugs, topiramate
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.